Botulinum toxin injection into the pylorus is reported to improve gastric emptying in gastroparesis. Classically, botulinum toxin inhibits acetylcholine (ACh) release from cholinergic nerves in skeletal muscle. Aim: To determine the effects of botulinum toxin on pyloric smooth muscle. Methods: Guinea pig pyloric muscle strips were studied in vitro. Botulinum toxin type A was added; electric field stimulation (EFS) was performed every 30 mins for 6 hrs. ACh 100 µM-induced contractile responses were determined prior to and after 6 hrs. Results: Botulinum toxin caused a concentration dependent decrease of pyloric contractions to EFS. At a low concentration (2 units/ml), botulinum toxin decreased pyloric contractions to EFS by 43+9% without affecting ACh-induced contractions. At higher concentrations (10 units/ml), botulinum toxin decreased pyloric contraction to EFS by 75+7% and decreased ACh-induced contraction by 79+9%. Conclusions: Botulinum toxin inhibits pyloric smooth muscle contractility. At a low concentration, botulinum toxin decreases EFS-induced contractile responses without affecting ACh-induced contractions suggesting inhibition of ACh release from cholinergic nerves. At higher concentrations, botulinum toxin directly inhibits smooth muscle contractility as evidenced by the decreased contractile response to ACh.
Introduction
Treatment of symptomatic gastroparesis is primarily with prokinetic agents that increase antral contractility, improve antroduodenal coordination, and accelerate gastric emptying.
Increased gastric outlet resistance due to pyloric sphincter dysfunction or pylorospasm has been described, primarily in diabetic gastroparesis (16) . This pylorospasm might also cause a delay in gastric emptying and result in gastroparetic symptoms.
Botulinum toxin injection into the lower esophageal sphincter (LES) decreases LES tone
and improves symptoms in achalasia (21) . Botulinum toxin injection into the pyloric sphincter is reported to improve gastric emptying and reduce dyspeptic symptoms in patients with gastroparesis (7, 14, 17) .
Classically, in striated muscle, botulinum toxin inhibits acetylcholine release from cholinergic nerves (10) . Botulinum toxin A selectively cleaves the synaptic protein SNAP-25, leading to inability of synaptic vesicles containing neurotransmitters to undergo exocytosis and release of neurotransmitters (2) . In gastrointestinal smooth muscle, botulinum toxin appears to also reduce cholinergic transmission by inhibiting acetylcholine release, as shown in in vitro (1, 15) and in vivo (20, 23) studies. SNAP-25, the substrate for botulinum toxin, is also present in gastrointestinal smooth muscle suggesting an additional site for botulinum toxin (13) . The aim of this study was to determine the effects and mechanism of action of botulinum toxin on pyloric and antral smooth muscle.
Materials and Methods
Pyloric and antral muscle strip preparation Guinea pigs (Covance Research Products, Incorporated. Denver, PA) weighing approximately 400 to 450 grams were used for this study. This study was approved by the IACUC Committee at Temple University School of Medicine. The stomach with pylorus and proximal duodenum were removed after the guinea pig had been sacrificed by CO 2 asphyxiation.
The stomach was opened along the longitudinal axis and rinsed with Krebs-bicarbonate buffer (composition in mM: NaCl, 120; KCl, 4.6; CaCl 2 , 2.5; MgCl 2 , 1.2; NaHCO 3 , 22; NaH 2 PO 4 , 1.2, and glucose, 11.5; oxygenated with 95% O 2 , 5% CO 2 ; pH 7.4).
The mucosa was removed from the antrum and pylorus. Antral and pyloric circular muscle strips were prepared and suspended in 10 ml organ baths containing Krebs-bicarbonate buffer (temperature 37 o C). In general, from each guinea pig, 2 antral muscle strips and 2 pyloric muscle strips were used. Muscle tension was measured along the circular muscle direction using an isometric force transducer (FT .03C, Grass Instruments Co., AstroMed, W. Warwick, RI).
The muscle strips were suspended between platinum electrodes placed adjacent and parallel to the long axis of the muscle strip. The electrodes were connected to an electric stimulator (Model #SD9, Grass Instruments Co., Astor-Med, W. Warwick, RI). After a 30 min equilibration period, the preparations were stretched until the contractile force to acetylcholine 100 µM was maximal (L max ).
Experimental Protocols
Muscle strips were studied in vitro for their contractile responses to electric field stimulation (EFS) and acetylcholine (ACh). Electric field stimulation (EFS) with 2-16 Hz, 100 V, 0.5 msec pulse width duration (square wave), 60 sec train duration parameters were used to activate the intrinsic nerves. L-NAME 100 µM was added to inhibit nitric oxide-mediated relaxation. After initial control responses to EFS and ACh 100 µM, botulinum toxin type A (Botox; Allergan, Inc.; Irvine, CA) was added in concentrations of 2, 4, or 10 units/ml; EFS (4 Hz, 60 sec) was performed every 30 minutes for 6 hrs in the continued presence of botulinum toxin. ACh 100 µM-induced contractile responses were also determined prior to and 6 hrs after botulinum toxin incubation. Control muscle strips were also studied with the same protocol but without the addition of botulinum toxin. In additional studies, the contractile responses to substance P (Sigma Chemical Co., St Louis, MO) was performed before and after 6 hours of incubation with botulinum toxin in a similar protocol as described above for ACh and EFS.
Data Analysis
Contractile responses to ACh, substance P, and EFS were measured as the maximal In subsequent experiments, the effect of botulinum toxin was determined on EFS and substance P-induced contractions of the pylorus. Botulinum toxin (10 units/ml) decreased the pyloric contractile responses to EFS by 24+11% (p=0.05) after 6 hour incubation in botulinum toxin, but had no effect on substance P (1 µM)-induced contractions (7+13% inhibition) ( Figure   5 ). In additional experiments, the effect of botulinum toxin was tested to a higher concentration of substance P, namely 10 µM. Botulinum toxin 10 units/ml decreased EFS-induced pyloric contractions by 25+2% (p<0.01) after a 6 hour incubation in botulinum toxin, but did not affect the contraction to substance P 10 µM (128+32% of control; p>0.10).
Antrum

General observations
In normal Krebs solution, EFS produced contractile responses in 13 of 22 (59%) antral muscle strips and a relaxation in 9 of 22 muscle strips (41%) antral smooth muscle strips. The addition of L-NAME 100 µM caused a contractile response in all antral muscle strips averaging 2.4+0.3 gm. Antral contractions to EFS in the presence of L-NAME were completely inhibited by atropine 1 µM or TTX 1 µM indicating activation of cholinergic nerves. ACh-induced contractions were inhibited by atropine but not TTX indicating a direct smooth muscle effect of ACh on antral smooth muscle.
Effect of botulinum toxin A and atropine
Botulinum toxin had similar inhibitory effects on antral smooth muscle as in the pylorus The inhibitory effects on the antrum tended to be less pronounced than in the pylorus, but direct statistical comparison of this did not reach statistical significance. At 2 units/ml, botulinum toxin reduced the EFS-induced contractions in the pylorus by 43+9% whereas in the antrum by only 22+27% (p=0.484). Among all the concentrations (0, 2, 4, 10 units/ml), two way ANOVA for the percent inhibition at the end of 6 hours incubation with factors concentration of botulinum toxin and location (antrum vs pylorus) was not significant (F=0.052; p=0.820).
Discussion
Our study has shown that botulinum toxin inhibits pyloric smooth muscle contractility.
There appears to be two mechanisms for botulinum toxin to decrease pyloric sphincter contractility: inhibition of ACh release and direct inhibition of smooth muscle contractility. At a low concentration, botulinum toxin decreases EFS-induced contractile responses without affecting ACh-induced contractions suggesting inhibition of ACh release from cholinergic nerves. At higher concentrations, however, botulinum toxin appears to directly inhibit smooth muscle contractility as evidenced by the decreased contractile response to ACh.
The experimental protocol used in this study involved incubation of the muscle strips to botulinum toxin for a prolonged period (6 hours). The inhibitory effects of botulinum toxin on EFS-induced contractions were not immediate; the onset of the inhibitory effect was gradual and slowly progressive. This time dependent effect may be related to either the mechanism of action of botulinum toxin or diffusion of the toxin into the tissue. The inhibitory effects were also concentration dependent in the concentration range of 2 to 10 units/ml. At the end of 6 hours, the contractile effect to EFS was inhibited by 43% with 2 units/ml botulinum toxin and by 75% with 10 units/ml. By comparison, atropine which blocks muscarinic cholinergic receptors nearly completely abolished EFS -induced contractions. Studies in hippocampal slices have also shown that the inhibitory effect of botulinum toxin A is time and concentration-dependent (19) . nerves (15, 24) . In rabbit hippocampal slices, although the release of ACh is most sensitive, botulinum A toxin incubation also inhibited noradrenalin and 5-HT release (19) . In guinea pig uterine artery, botulinum toxin appears to affect EFS-induced contractility by several mechanisms including nearly abolishing contractions due to ACh release, reducing neuropeptidemediated contractions, but without an affect on nitric oxide mediated relaxations (18) . Other studies in gastrointestinal smooth muscle have suggested that botulinum toxin has no effect on nonadrenergic, noncholinergic inhibitory response of the guinea pig fundus (22) and the lower esophageal sphincter (4).
Our studies showed that higher concentrations of botulinum toxin (10 units/ml) directly inhibits cholinergic smooth muscle contractility as evidenced by the decreased contractile response to ACh. Acetylcholine, in this study, acts primarily on smooth muscle muscarinic receptors to directly contract the muscle, since the contractions to ACh were inhibited by atropine, but not by tetrodotoxin. This suggests high concentrations of botulinum toxin may have a direct inhibitory effect on smooth muscle contractility. Our further studies showed that botulinum toxin decreased contractile responses to ACh but not to substance P. Substance P contracts the pylorus predominantly by a direct effect on smooth muscle. This differential effect of botulinum toxin on ACh but not substance P-induced contractions may potentially offer some insight into the mechanism of botulinum toxin as it appears not to be a nonspecific effect on muscle contractility which would decrease contractility to a variety of agonists. High concentrations of botulinum toxin affects smooth muscle contractility to cholinergic muscarinic muscular transmission, possibly at the receptor level or on intracellular pathways. The exact cellular mechanism of botulinum toxin inhibiting acetylcholine-induced contractions was not detailed in this study. Interestingly, SNAP-25, the substrate for botulinum toxin, has also been found to be present in gastrointestinal smooth muscle (12) . This suggests an additional site for botulinum toxin in regulating muscle contractility, besides the classical effect of acting on presynaptic neurons to reduce acetylcholine release (12) . Botulinum toxin light chain administered intracellularly in smooth muscle cells has been shown to increase potassium channel currents (12) . This would tend to hyperpolarize the muscle membrane and result in a decrease in muscle tone. SNAP-25 may have an additional role in inhibiting calcium channels (11, 12, 25) . Both of these would decrease ACh-induced contractions. It is not known whether smooth muscle cells have the membrane pathways to internalize the toxin to act on intracellular SNAP-25, as are present on neurons (13) . Further studies are needed to reconcile the apparent neurotransmitter (ACh) specific effect of botulinum toxin on the pylorus as shown in this study with the putative effects on potassium and calcium channels shown in other studies.
What is the clinical corollary of these in vitro studies? Delayed gastric emptying in diabetic gastroparesis is associated with antral hypomotility, increased pyloric tone and pylorospasm. Increased gastric outlet resistance due to pyloric sphincter dysfunction or pylorospasm has been described, primarily in diabetic gastroparesis (5, 16) and may be in part responsible for the delay in gastric emptying and resultant symptoms. Botulinum toxin injected into the pylorus in patients with gastroparesis might relax the pylorus and facilitate gastric emptying. Several small open label studies have shown this in diabetic gastroparesis (7, 14) and in idiopathic gastroparesis (17) . Intrasphincteric injection of botulinum toxin has been shown to reduce pyloric pressure waves and pylorospasm in diabetic gastroparesis, but had no effect on antral contractility (5, 8) .
Our study showed that botulinum toxin, in addition to decreasing pyloric contractility, also decreased antral smooth muscle contractility in vitro. Diffusion of botulinum toxin into the antrum or a misplaced injection might occur when attempting to inject the pylorus using an endoscopic sclerotherapy needle. The inhibitory effect of botulinum toxin on EFS-induced antral contractility extrapolated to the in vivo condition might cause antral hypomotility and worsen gastric emptying. Postprandial antral contractility, as measured by antral manometry, correlates with gastric emptying of a solid meal (3). In our in vitro study, the pylorus tended to be more sensitive than the antrum to the inhibitory effect of botulinum toxin, however, direct comparison of this failed to reach statistical significance.
We studied the effects of botulinum toxin on both antral and pyloric muscle strips. It is also possible that the observed direct smooth muscle effect of the toxin may be peculiar to an in vitro system. Our experiments used time controls with Krebs incubation but did not use a protein control. Furthermore, we did not investigate if the effect of botulinum toxin is a temperature dependent. A natural extension of our in vitro studies is to investigate if these inhibitory effects of botulinum toxin occur in vivo by injecting the pylorus, in a similar manner to that performed clinically, and measuring changes in pyloric sphincter contractility. on ACh-induced pyloric contractions are shown. There was no effect on 2 and 4 units/ml botulinum toxin on the contractile response to ACh. In contrast, the highest concentration, 10 units/ml, caused a 79+9% inhibitory effect on ACh-induced contractions. Shown also is the near complete inhibition seen with atropine. There was a significant concentration-related effect of botulinum toxin in inhibit ACh-induced contractions in the pylorus using one way analysis of variance with factor of concentration of botulinum toxin (F=4.578; p=0.013). Only the concentration of botulinum toxin 10 units/ml was significantly different from control (F=7.57; p=0.019). 
